Puma Biotechnology to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceBusiness Wire • 08/31/23
Puma Biotechnology Announces FDA Clearance of IND for Alisertib in Small Cell Lung CancerBusiness Wire • 08/08/23
Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2023 Financial ResultsBusiness Wire • 07/20/23
Puma Biotechnology Announces Presentation of Biomarker Findings from a Phase II Study of Alisertib with Paclitaxel versus Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer at the 2023 ASCO Annual MeetingBusiness Wire • 06/04/23
Puma Biotechnology to Host Conference Call to Discuss First Quarter 2023 Financial ResultsBusiness Wire • 04/20/23
Puma Biotechnology Announces Publication of Phase II Clinical Trial of Alisertib in JAMA OncologyBusiness Wire • 03/14/23
Puma Biotechnology to Participate in a Panel Discussion at Cowen's 43rd Annual Health Care ConferenceBusiness Wire • 02/28/23
Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2022 Financial ResultsBusiness Wire • 02/16/23
Puma Biotechnology's NERLYNX® Included in NCCN Clinical Practice Guidelines for the Treatment of Breast Cancer with a HER2 MutationBusiness Wire • 02/01/23
Puma Biotechnology to Present at B. Riley Securities' 3rd Annual Oncology ConferenceBusiness Wire • 01/12/23
Puma Biotechnology Presents Updated Findings from the TBCRC-022 Trial at the 2022 San Antonio Breast Cancer SymposiumBusiness Wire • 12/07/22
Puma Biotech (PBYI)'s Technical Outlook is Bright After Key Golden CrossZacks Investment Research • 11/28/22